Singapore, May 6 -- UK-based Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced the successful adaptation of the Optimer-based test for Alzheimer's disease into an Enzyme-Linked Immunosorbent Assay (ELISA), a format widely accepted and used in hospital laboratories, in partnership with Neuro-Bio Ltd.

This advance in test development follows the recent demonstration of an Optimer-based biosensor test that showed a statistically significant difference in levels of a novel Alzheimer's disease biomarker between saliva samples from Alzheimer's patients and healthy patient controls.

Initial in-house validation of the plate-based ELISA assay at Aptamer...